References
Atchinson RW,
Castro BC and
Hammon WMD
(1965)
Adenovirus‐associated defective virus particles.
Science
149: 754–756.
Berns KI
(1990)
Parvoviridae and their replication
In: Fields BN,
Knipe DM,
Chanock RM et al. (eds)
Virology,
2nd edn,
Vol 2.
New York: Raven Press.
Cavalier‐Smith T
(1974)
Palindronic base sequences and replication of eukaryotic chromosome ends.
Nature
250: 467–470.
Clark KR,
Voulgaropoulou F,
Fraley DM and
Johnson PR
(1995)
Cell lines for the production of recombinant adeno‐associated virus.
Human Gene Therapy
6: 1329–1341.
Conway JE,
Rhys CM,
Zolotukhin I et al.
(1999)
High‐titer recombinant adeno‐associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV‐2 Rep and Cap.
Gene Therapy
6: 986–993.
Duan D,
Sharma P,
Yang J et al.
(1998)
Circular intermediates of recombinant adeno‐associated virus have defined structural characteristics responsible for long‐term episomal persistence in muscle tissue.
Journal of Virology
72: 8568–8577.
Duan D,
Yue Y,
Yan Z,
Yand J and
Engelhardt JF
(2000)
Endosomal processing limits gene transfer to polarized airway epithelia by adeno‐associated virus.
Journal of Clinical Investigation
105: 1573–1587.
Ferrari FK,
Samulski T,
Shenk T and
Samulski RJ
(1996)
Second‐strand synthesis is a rate‐limiting step for efficient transduction by recombinant adeno‐associated virus vectors.
Journal of Virology
70: 3227–3234.
Fisher KJ,
Gao GP and
Weitzman MD et al.
(1996)
Transduction with recombinant adeno‐associated virus for gene therapy is limited by leading‐strand synthesis.
Journal of Virology
70: 520–532.
Flotte TR,
Afione SA and
Zeitlin PL
(1994)
Adeno‐associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration.
American Journal of Respiratory Cell and Molecular Biology
11: 517–521.
Flotte TR,
Carter B,
Conard C et al.
(1996)
A phase I study of an adeno‐associated virus‐CFTR gene vector in adult CF patients with mild lung disease.
Human Gene Therapy
7: 1145–1159.
George‐Fries B,
Biederlack S,
Wolf J and
zur Hausen H
(1984)
Analysis of proteins, helper dependence and seroepidemiology of a new human parvovirus.
Virology
134: 64–71.
Hoggan MD,
Blacklow NR and
Rowe WP
(1966)
Studies of small DNA viruses found in various adenovirus preparations: physical, biological and immunological characteristics.
Proceedings of the National Academy of Sciences of the United States of America
55: 1467–1474.
Im DS and
Muzyczka N
(1990)
The AAV origin binding protein Rep68 is an ATP‐dependent site‐specific endonuclease with DNA helicase activity.
Cell
61: 447–457.
Kaplitt MG,
Leone P,
Samulski RJ et al.
(1994)
Long‐term gene expression and phenotypic correction using adeno‐associated virus vectors in the mammalian brain.
Nature Genetics
8: 148–154.
Kay MA,
Manno CS,
Ragni MV et al.
(2000)
Evidence for gene transfer and expression for factor IX in haemophilia B patients treated with an AAV vector.
Nature Genetics
24: 257–261.
Kotin RM,
Siniscalco M,
Samulski RJ et al.
(1990)
Site‐specific integration by adeno‐associated virus.
Proceedings of the National Academy of Sciences of the United States of America
87: 2211–2215.
Mayor HD,
Drake S,
Stahmann J and
Mumford DM
(1976)
Antibodies to adeno‐associated satellite virus and herpes simplex in sera from cancer patients and normal adults.
American Journal of Obstetrics and Gynecology
126: 100–104.
Samulski RJ,
Chang LS and
Shenk T
(1989)
Helper‐free stocks of recombinant adeno‐associated viruses: normal integration does not require viral gene expression.
Journal of Virology
63: 3822–3828.
Samulski RJ,
Zhu X,
Xiao X et al.
(1991)
Targeted integration of adeno‐associated virus (AAV) into human chromosome 19.
EMBO Journal
10: 3941–3950.
Smith RH and
Kotin RM
(1998)
The Rep52 gene product of adeno‐associated virus is a DNA helicase with 3′ to 5′ polarity.
Journal of Virology
72: 4874–4881.
Summerford C and
Samulski RJ
(1998)
Membrane‐associated heparan sulfate proteoglycan is a receptor for adeno‐associated virus type 2 virions.
Journal of Virology
72: 1438–1445.
Sun L,
Li J and
Xiao X
(2000)
Overcoming adeno‐associated virus vector size limitation through viral DNA heterodimerization.
Nature Medicine
6: 599–602.
Xiao X,
Li J and
Samulski RJ
(1998)
Production of high‐titer recombinant adeno‐associated virus vectors in the absence of helper adenovirus.
Journal of Virology
72: 2224–2232.
Xiao X,
Li J and
Samulski RJ
(1996)
Efficient long‐term gene transfer into muscle tissue of immunocompetent mice by adeno‐associated virus vector.
Journal of Virology
70: 8098–8108.
Xiao X,
Xiao W,
Li J and
Samulski RJ
(1997)
A novel 165 base‐pair terminal repeat sequence is the sole cis requirement for the adeno‐associated virus life cycle.
Journal of Virology
71: 941–948.
Zolotukhin S,
Byrne BJ,
Mason E et al.
(1999)
Recombinant adeno‐associated virus purification using novel methods improves infectious titer and yield.
Gene Therapy
6: 973–985.
Further Reading
Berns KI and
Giraud C
(1996)
Biology of adeno‐associated virus.
Current Topics in Microbiology and Immunology
218: 1–23.
Muzyczka N
(1992)
Use of adeno‐associated virus as a general transduction vector for mammalian cells.
Current Topics in Microbiology and Immunology
158: 97–129.
Samulski RJ,
Sally M and
Muzyczka N
(1999)
Adeno‐associated viral vectors.
In: Friedmann T (ed.)
Development of Human Gene Therapy,
pp. 131–172.
Cold Spring Harbor: Cold Spring Harbor Laboratory Press.
Tijssen P (ed.)
(1990)
Handbook of Parvoviruses.
Boca Raton, FL: CRC Press.